taurine has been researched along with Parkinson Disease in 16 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Homotaurine is a natural compound of red algae, which has been demonstrated to have a neuroprotective effect and has been evaluated as a possible therapeutic agent for Alzheimer's disease." | 2.80 | Homotaurine in Parkinson's disease. ( De Nigris, F; Fasano, A; Ricciardi, L; Specchia, A, 2015) |
| " Interestingly, plasma taurine levels negatively correlated with cumulative levodopa dosage in tPD." | 1.43 | Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment. ( Ding, J; Jiang, S; Tong, Q; Xu, Q; Yuan, Y; Zhang, K; Zhang, L; Zhang, R, 2016) |
| "Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss." | 1.26 | Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, K | 1 |
| Zhang, B | 2 |
| Tian, T | 1 |
| Shi, G | 1 |
| Zhang, C | 1 |
| Li, G | 1 |
| Huang, M | 1 |
| Ren, X | 1 |
| Hinchie, A | 1 |
| Swomley, A | 1 |
| Powell, DK | 1 |
| Butterfield, DA | 1 |
| Abuirmeileh, AN | 1 |
| Abuhamdah, SM | 1 |
| Ashraf, A | 1 |
| Alzoubi, KH | 1 |
| Stiles, L | 1 |
| Zheng, Y | 1 |
| Smith, PF | 1 |
| Ricciardi, L | 1 |
| De Nigris, F | 1 |
| Specchia, A | 1 |
| Fasano, A | 1 |
| Zhang, L | 2 |
| Yuan, Y | 1 |
| Tong, Q | 1 |
| Jiang, S | 1 |
| Xu, Q | 1 |
| Ding, J | 1 |
| Zhang, R | 1 |
| Zhang, K | 1 |
| Hajj, R | 1 |
| Milet, A | 1 |
| Toulorge, D | 1 |
| Cholet, N | 1 |
| Laffaire, J | 1 |
| Foucquier, J | 1 |
| Robelet, S | 1 |
| Mitry, R | 1 |
| Guedj, M | 1 |
| Nabirotchkin, S | 1 |
| Chumakov, I | 1 |
| Cohen, D | 1 |
| Mehta, NJ | 1 |
| Asmaro, K | 1 |
| Hermiz, DJ | 1 |
| Njus, MM | 1 |
| Saleh, AH | 1 |
| Beningo, KA | 1 |
| Njus, D | 1 |
| Morales, I | 1 |
| Dopico, JG | 1 |
| Sabate, M | 1 |
| Gonzalez-Hernandez, T | 1 |
| Rodriguez, M | 1 |
| Plaitakis, A | 1 |
| Berl, S | 1 |
| Tanaka, Y | 1 |
| Mizuno, Y | 1 |
| Hayes, J | 1 |
| Tipton, KF | 1 |
| Bianchi, L | 1 |
| Corte, LD | 1 |
| Purdy, A | 1 |
| Hahn, A | 1 |
| Barnett, HJ | 1 |
| Bratty, P | 1 |
| Ahmad, D | 1 |
| Lloyd, KG | 1 |
| McGeer, EG | 1 |
| Perry, TL | 4 |
| Bratty, PJ | 1 |
| Hansen, S | 3 |
| Kennedy, J | 1 |
| Urquhart, N | 1 |
| Dolman, CL | 1 |
| Bergeron, C | 1 |
| Steele, JC | 1 |
| McLachlan, DR | 1 |
| Kloster, M | 1 |
1 trial available for taurine and Parkinson Disease
| Article | Year |
|---|---|
Homotaurine in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disorders of Excessive Somnolence; Female; Humans; | 2015 |
15 other studies available for taurine and Parkinson Disease
| Article | Year |
|---|---|
Taurine protects dopaminergic neurons in paraquat-induced Parkinson's disease mouse model through PI3K/Akt signaling pathways.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Paraquat; Parkinson | 2022 |
Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Corpus Striatum; Disease Models, Animal; Female; Gene Kno | 2019 |
Protective effect of caffeine and/or taurine on the 6-hydroxydopamine-induced rat model of Parkinson's disease: Behavioral and neurochemical evidence.
Topics: Animals; Apomorphine; Behavior, Animal; Caffeine; Corpus Striatum; Disease Models, Animal; Dopamine; | 2021 |
The effects of electrical stimulation of the peripheral vestibular system on neurochemical release in the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Electric Stimulation; Electric S | 2018 |
Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity | 2016 |
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Topics: Acamprosate; Animals; Baclofen; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Hypochlorite converts cysteinyl-dopamine into a cytotoxic product: A possible factor in Parkinson's Disease.
Topics: Animals; Cell Survival; Cytotoxins; Dopamine; Humans; Hypochlorous Acid; Models, Biological; Oxidati | 2016 |
Substantia nigra osmoregulation: taurine and ATP involvement.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adenosine Triphosphate; Animals; Choline; Dose-Response Relati | 2007 |
Oral glutamate loading in disorders with spinocerebellar and extrapyramidal involvement: effect on plasma glutamate, aspartate and taurine.
Topics: Aspartic Acid; Atrophy; Basal Ganglia Diseases; Cerebellar Diseases; Cerebellum; Friedreich Ataxia; | 1983 |
[GABA, glutamate, aspartate, glycine, and taurine contents in spinocerebellar degeneration and parkinsonism].
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Brain Chemistry; Cerebellar Ataxia; Chromatography, High Pr | 1984 |
Complexities in the neurotoxic actions of 6-hydroxydopamine in relation to the cytoprotective properties of taurine.
Topics: Aconitate Hydratase; Adrenergic Agents; Animals; Dopamine; Extracellular Space; gamma-Aminobutyric A | 2001 |
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate | 1979 |
Hereditary mental depression and Parkinsonism with taurine deficiency.
Topics: Age Factors; Aged; Antidepressive Agents; Body Weight; Brain; Depression; Electroconvulsive Therapy; | 1975 |
Brain amino acid contents are dissimilar in sporadic and Guamanian amyotrophic lateral sclerosis.
Topics: Aged; Amino Acids; Amyotrophic Lateral Sclerosis; Brain; Female; gamma-Aminobutyric Acid; Glutamates | 1990 |
Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
Topics: Amino Acid Metabolism, Inborn Errors; Amino Acids; Aminobutyrates; Autopsy; Basal Ganglia; Brain; Br | 1973 |